Novo Nordisk/NVO
$126.69
-0.47%-
1D1W1MYTD1YMAX
About Novo Nordisk
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Ticker
NVO
Sector
Healthcare
Trading on
NYSE
Industry
Biotechnology & Drugs
CEO
Lars Fruergaard Joergensen
Employees
66,015
Headquarters
Bagsvaerd, Denmark
Website
www.novonordisk.com
Novo Nordisk Metrics
BasicAdvanced
$432B
Market cap
44.33
P/E ratio
$2.87
EPS
0.41
Beta
$1.01
Dividend rate
0.4%
Dividend yield
Price and volume
Market cap
$432B
Beta
0.41197
52-week high
$138.28
52-week low
$75.56
Average daily volume
4.8M
Dividend rate
$1.01
Financial strength
Current ratio
0.703
Quick ratio
0.5
Long term debt to equity
16.949
Total debt to equity
27.224
Dividend payout ratio (TTM)
47.03%
Enterprise value to free cash flow
237.875
Management effectiveness
Return on assets (TTM)
32.53%
Return on equity (TTM)
99.87%
Return on investment (TTM)
71.03%
Valuation
Price to earnings (TTM)
44.333
Price to revenue (TTM)
12.267
Price to book
39.788
Price to tangible book (TTM)
76.291
Price to free cash flow (TTM)
360.228
Five year average dividend yield
1.31%
Dividend yield (TTM)
0.79%
Forward dividend yield
0.4%
Growth
Revenue change (TTM)
29.72%
Earnings per share change (TTM)
48.15%
3-year revenue growth
22.31%
3-year earnings per share growth
27.4%
3-year dividend per share growth
20.59%
What the Analysts think about Novo Nordisk
Analyst Ratings
Majority rating from 9 analysts.
Price Targets
Average projection from 8 analysts.
High $162.65
Low $129.72
$126.69
Current price
$145.91
Average price target
Novo Nordisk Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
DKK 65B
-0.78%
Net income
DKK 25B
15.68%
Profit margin
38.87%
16.59%
Novo Nordisk Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
DKK 4.39
DKK 4.32
DKK 5.00
DKK 4.91
-
Expected
DKK 4.32
DKK 4.41
DKK 5.00
DKK 4.48
DKK 5.14
Surprise
1.62%
-2.09%
0.09%
9.55%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR
Upcoming events
FAQs
What’s the current market cap for Novo Nordisk stock?
Novo Nordisk (NVO) has a market cap of $432B as of May 09, 2024.
What is the P/E ratio for Novo Nordisk stock?
The price to earnings (P/E) ratio for Novo Nordisk (NVO) stock is 44.33 as of May 09, 2024.
Does Novo Nordisk stock pay dividends?
Yes, the Novo Nordisk (NVO) stock pays dividends to shareholders. As of May 09, 2024, the dividend rate is $1.00744 and the yield is 0.4%. Novo Nordisk has a payout ratio of 47.03% on a trailing twelve-month basis.
When is the next Novo Nordisk dividend payment date?
The next Novo Nordisk (NVO) dividend payment date is unconfirmed.
What is the beta indicator for Novo Nordisk?
Novo Nordisk (NVO) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
What is the Novo Nordisk stock price target?
The target price for Novo Nordisk (NVO) stock is $145.91, which is 15.17% above the current price of $126.69. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.
Buy or sell Novo Nordisk stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.